Stocksigma LogoStocksigma Logo

Zydus Lifesciences Settles US Generic Pricing Antitrust Litigation for USD 5.9 Million

Zydus Lifesciences announced on 5th Sep'26 that its wholly owned US subsidiary, Zydus Pharmaceuticals USA Inc

Zydus Lifesciences Settles US Generic Pricing Antitrust Litigation for USD 5.9 Million

Zydus Lifesciences Ltd 路 Others (Uncategorized) 路 05 Sept 2026, 10:43 pm

Zydus Lifesciences Settles US Generic Pricing Antitrust Litigation for USD 5.9 Million Zydus Lifesciences announced on 5th Sep'26 that its wholly owned US subsidiary, Zydus Pharmaceuticals USA Inc. (ZPUI), entered into a settlement agreement with a putative class of Indirect Reseller Plaintiffs. The agreement resolves litigation under MDL No. 2724 (*In re Generic Pharmaceuticals Pricing Antitrust Litigation*) pending in the US District Court for the Eastern District of Pennsylvania. Under the terms, ZPUI will pay USD 5.9mn for a full and final release of all claims, executed without any admission of fault or wrongdoing.

Original exchange filing (PDF)

More announcements from Zydus Lifesciences Ltd

All Zydus Lifesciences Ltd announcements